Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis

IMPORTANCE: Checkpoint inhibitors have a unique mechanism of action that differs from chemotherapy or targeted therapies. The validity of objective response rate (ORR) as a surrogate for progression-free survival (PFS) and overall survival (OS) in checkpoint-inhibitor trials is uncertain. OBJECTIVE:...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Oncol
Autors principals: Ritchie, Georgia, Gasper, Harry, Man, Johnathan, Lord, Sally, Marschner, Ian, Friedlander, Michael, Lee, Chee Khoon
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2018
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5885200/
https://ncbi.nlm.nih.gov/pubmed/29470579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.5236
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars